Relugolix
Cat. No.：YN321063
CAS No. ：737789-87-6
规格
价格(RMB)
库存
| 产品名称: | Relugolix |
| CAS No.: | 737789-87-6 |
| Chemical Name: | N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N-methoxy-urea |
| Synonyms: | 瑞卢戈利; TAK-385 |
| 分子量: | 623.63 |
| 分子式: | C₂₉H₂₇F₂N₇O₅S |
| SMILES: | O=C(NOC)NC1=CC=C(C(S2)=C(CN(C)C)C(C(N3C4=NN=C(OC)C=C4)=O)=C2N(CC5=C(F)C=CC=C5F)C3=O)C=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Relugolix (TAK-385) 是一种有效的，具有口服活性，非肽性促性腺激素释放激素(GnRH) 的拮抗剂。与 TAK-013 (HY-100209_x000D_ ) 相比，Relugolix 对人 (IC50=0.33 nM) 和猴子 (IC50=0.32 nM) 的受体具有高亲和力和强拮抗活性。Relugolix 用于性激素依赖性疾病的研究，如子宫内膜异位症、子宫肌瘤、前列腺癌等。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Miwa, K., Hitaka, T., Imada, T., et al.Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptorJ. Med. Chem.54(14),4998-5012(2011)
Nakata, D., Masaki, T., Tanaka, A., et al.Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in miceEur. J. Pharmacol.723,167-174(2014)
